Rebamipide SN is commonly used to help with conditions presenting with localized discomfort in the gastrointestinal tract.

Supporting Healing and Symptomatic Relief

This medicine is applied in clinical settings that involve active mucosal injury and conditions characterized by periods of heightened symptoms, such as gastric ulcers, acute exacerbations of chronic gastritis, and oral aphthae (canker sores). It helps address symptom clusters related to inflammatory or irritative states and contributes to easing discomfort during these episodes.

Prophylaxis and Patient Benefit

Rebamipide SN is also relevant when supportive symptom management is appropriate for patients requiring long-term use of medications known to affect the stomach lining, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It supports the patient during difficult episodes by offering supportive therapeutic benefit and may assist with maintaining functional stability against drug-induced strain. It is also used to help with symptom management in acute and chronic gastritis and is used to address painful, recurring episodes of oral aphthae. It ultimately helps improve day-to-day comfort when symptoms are more noticeable.

Quick Fact: Relief for Upper Abdominal Discomfort and Symptom Management in Gastric Ulcers

Regulatory References

1. Japanese Official Drug Information Sheet

The eligibility profile for Rebamipide SN is defined by official regulatory documentation that identifies the patient populations permitted to use the medicine and those who are restricted or contraindicated.

Absolute Exclusion (Contraindication)

Rebamipide SN must not be used by patients with a history of hypersensitivity or allergic reaction to the active ingredient, rebamipide, or any other component of the tablet.

---

Age-Related Eligibility

Use is established for adult patients receiving treatment for labeled indications. However, the medicine is not recommended for children, infants, or adolescents because the safety and effectiveness in the pediatric population have not been officially established. Special care is required when administering Rebamipide SN to elderly patients, who may experience greater physiological sensitivity.

---

Conditional and Restricted Use

Patients with renal impairment also require special care due to potential alterations in drug concentration and elimination time. For pregnant or possibly pregnant women, safety has not been established, and administration is restricted to cases where the anticipated therapeutic benefit is determined to outweigh any potential risk. Nursing should be interrupted during the period of treatment.

Interactions with other medicines and products

Official regulatory documentation on the interaction profile of Rebamipide SN (Rebamipide) indicates a generally low potential for conventional drug-drug interactions. The majority of the substance is excreted unchanged, resulting in limited involvement of hepatic enzymes that typically process many co-administered medicines.

Documented Pharmacokinetic and Administration Patterns

Interaction Entity	Official Regulatory Statement
Drug–Drug Interactions	The drug is documented for co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a practice intended to mitigate mucosal injury, which represents a supportive pharmacodynamic use.
Contraindications	No medicinal products are explicitly designated as contraindicated combinations with rebamipide in official regulatory labels.
Food Intake	Official data indicates that taking the medicine with food does not significantly affect its overall bioavailability.
Timing Requirements	There are no mandatory timing separation rules specified for co-administered medicines.

Substance and Population-Specific Restrictions

Regulatory authorities advise against excessive alcohol consumption, stating that this may increase the risk of adverse effects associated with the medicine.

A key pharmacokinetic consideration is documented for specific populations: patients with renal impairment. In this group, studies showed that plasma concentrations and the elimination half-life were higher and longer following administration, which is a required label disclosure related to the drug's elimination route.

The mechanism of action for Rebamipide is defined by a multi-modal effect that modifies the intrinsic defense systems of the upper gastrointestinal (GI) mucosa at the biochemical level, independent of acid suppression.

---

Modulation of the Mucosal Barrier via Prostaglandins

This core mechanism focuses on stabilizing the Prostaglandin Pathway. The molecule acts by inhibiting the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which reduces the catabolism of protective prostaglandins ( PGE2 and PGI2). This targeted enzyme modulation enhances the secretion of the physical mucus-bicarbonate layer and modulates local mucosal blood flow. This results in an alteration of the physical characteristics and resilience of the barrier against endogenous chemical stressors.

---

Mechanistic Consequences of Antioxidant Activity

Rebamipide directly targets the cascade of cellular damage through its antioxidant activity and anti-inflammatory properties. It functions as a scavenger of Reactive Oxygen Species (ROS), which are molecules that induce cellular oxidative stress and local damage. The suppression of these free radicals, alongside the modulation of pro-inflammatory cytokines, may alter the cascade that leads to cellular damage and modulates the localized inflammatory signaling within the GI lining.

---

Mechanism of Epithelial Restitution and Proliferation

The drug engages a trophic mechanism that supports the restoration of the mucosal lining. This involves stimulating signaling pathways, including those related to Epidermal Growth Factor (EGF), which enhances the rate of epithelial cell migration and proliferation. This mechanism supports the restitution of the mucosal surface, facilitating the biological process of structural and functional integrity restoration within the damaged tissue.

How to use Rebamipide SN

Rebamipide SN is administered via the oral route using a standard 100 mg tablet formulation. The usage protocol is designed to provide standardized application across clinical settings.

Standard Dosing Regimen

The standard adult dosing regimen requires a unit dose of 100 mg to be taken three times daily (TID), resulting in a Total Daily Dose of 300 mg. This divided frequency is used for conditions requiring active treatment courses, such as gastric ulcers, and for supportive maintenance, like the prevention of NSAID-induced conditions. For the treatment of gastric ulceration, the schedule is often structured as one tablet in the morning, one in the evening, and a final tablet before going to bed.

The administration of Rebamipide is not tied to meals and may be taken with or without food, as food consumption does not significantly alter the medicine's bioavailability.

Special Population and Procedural Rules

The standard regimen is applied with special care in older adults due to increased physiological sensitivity. Similarly, patients with renal impairment may require clinical monitoring of the dose, given observed alterations in the drug’s elimination profile.

Should a scheduled dose be forgotten, it is typically taken as soon as it is remembered. However, if the time for the next scheduled dose is imminent, the missed dose is skipped. Under no circumstances are two doses combined at once to compensate for the missed one.

Rebamipide SN: Recent Clinical Evidence

Evidence for Healing Gastric Ulcers

The compound Rebamipide was the subject of research exploring outcomes in patients with gastric ulcers. Research utilized Randomized Controlled Trials (RCTs) and Meta-Analyses to monitor the progress of adult patients by measuring endoscopic healing rates (ulcer closure to a scar) and subsequent ulcer recurrence rates. Findings from these trials describe patterns observed in the studies that reported measurements of ulcer closure. Research examined ulcer recurrence and reported patterns of change in some observed groups over the intermediate follow-up duration. However, the existing evidence is limited in fully characterizing the long-term patterns of recurrence beyond the typical 16-week observation periods.

Evidence for Chronic and Erosive Gastritis

The compound was also the subject of research exploring outcomes in patients with chronic and erosive gastritis, evaluated in short-term RCTs and Real-World Observational Studies. These studies monitored endoscopic findings, such as the rates of erosion improvement, redness, and edema, as well as patient-reported outcomes describing perceived discomfort. Short-term trials reported changes measured in endoscopic scores related to erosion and inflammation. Active-control studies evaluated whether the compound met pre-defined non-inferiority thresholds when compared to other established treatments. The follow-up durations were limited in many key trials, meaning research characterizing the long-term effects on disease modification are not fully established.

Evidence for Preventing NSAID-Related Gastrointestinal Injury

Evidence for preventing gastrointestinal injury from Non-Steroidal Anti-Inflammatory Drug (NSAID) use is derived from RCTs, Systematic Reviews, and Meta-Analyses. Studies examined the incidence rate of new ulcers and endoscopic assessment of mucosal injury in both the stomach and the small intestine (enteropathy scores). These studies describe patterns observed where the compound was associated with lower measurements of small bowel mucosal injury scores. Systematic reviews suggest that the medicine may be associated with a reduced rate of ulcer incidence in the stomach during periods of high physiological strain. Data for certain groups remain insufficient, and further research is ongoing to fully confirm the value of this preventative strategy.

Common questions about Rebamipide SN (FAQ)

Q: What kind of stomach issues is Rebamipide SN meant to help with?

According to official product information, Rebamipide SN is prescribed for the treatment of gastric ulcers. The medicine is also used to address symptoms described in the official product information related to certain types of acute or chronic gastritis.

Q: Can Rebamipide SN be used alongside other ulcer medications?

Regulatory documents indicate a low potential for drug-drug interactions. This finding suggests a low likelihood of pharmacokinetic interference with many commonly co-administered medicines.

Q: Can Rebamipide SN be taken at the same time as antacids?

Official documents state that there are no mandatory timing separation rules for co-administered medicines. This regulatory statement relates to administration timing and suggests flexibility in use with other co-administered products.

Q: Can people with liver problems use Rebamipide SN?

Regulatory documents note that special care is considered due to documented rare occurrences of liver dysfunction and increases in liver enzyme levels. This potential requires clinical monitoring.

Q: Are there any specific requirements for monitoring while using Rebamipide SN?

Official labeling notes that periodic monitoring may be advised by a healthcare professional. This is due to the potential for rare but serious adverse reactions, such as changes in blood cell count (leukopenia) or liver function, that may require monitoring via blood tests.

Q: Do studies suggest Rebamipide SN can be used long-term?

Regulatory reviews of clinical evidence note that the long-term safety and effects on disease progression are generally not fully established. These reviews indicate that research limitations exist beyond typical clinical observation periods.

Q: Are there any warnings about Rebamipide SN and driving or operating machinery?

Official documents list dizziness and drowsiness as possible, though uncommon, adverse reactions associated with the medicine. These documents suggest a need for caution when assessing the ability to drive or operate machinery.

Q: How long does the effect of one dose of Rebamipide SN typically last?

Pharmacokinetic data shows the medicine has a short elimination half-life. This characteristic is generally consistent with the necessary frequency of administration described in official documents.

Q: Can Rebamipide SN interact with oral contraceptives?

Official documents suggest a low overall potential for pharmacokinetic drug-drug interactions. This is due to the medicine's minimal involvement with the major liver enzymes that typically process many co-administered drugs like oral contraceptives.

Q: Can Rebamipide SN be crushed or split if a person has trouble swallowing?

Official administration instructions specify that the tablet should be administered whole. There are generally no instructions provided in the official documents for crushing or splitting the tablets.

Q: What is the shelf life of Rebamipide SN tablets?

The official product information specifies a documented shelf life for Rebamipide SN tablets. This shelf life is valid when the medicine is stored under the recommended conditions, such as keeping it away from heat and moisture.

Q: Is there any data on Rebamipide SN use in patients with Helicobacter pylori?

Regulatory summaries of clinical trials may mention studies exploring the use of the medicine as part of certain H. pylori eradication regimens in some regions. This indicates the medicine has been examined in relation to the overall management of the condition.

Q: Can Rebamipide SN interact with vitamins or herbal supplements?

Official documents often emphasize the importance of informing a healthcare professional of all co-administered products. This includes non-prescription items such as herbal remedies and vitamins, due to the potential for unknown interactions.

Q: Do official documents mention any potential for dependence on Rebamipide SN?

The medicine is not classified as a controlled substance with a potential for abuse or dependence in official regulatory documents.

Q: Can people with high blood pressure use Rebamipide SN?

Official regulatory documents do not specify high blood pressure (hypertension) as a general contraindication or precaution for use.

Official Storage and Disposal Requirements

The storage of Rebamipide tablets must adhere strictly to the conditions specified in official regulatory documents to maintain product quality.

Condition	Requirement
Storage Temperature	Do not store above 30°C (86°F).
Protection	Keep away from direct sunlight, heat, and moisture.
Child Safety	Must be kept out of the sight and reach of children.
Packaging	Typically supplied in blister packs.

Unused or expired Rebamipide must be handled according to specific disposal rules. Regulatory instructions state to discard the remainder and not store any unused portion of the medicine. If no other specific directions are provided on the labeling, users should generally follow local environmental regulations for discarding unused medication into household trash, taking care to obscure identifying information on the container.